Marlijn de Beer1, Marc Engelen2, Björn M van Geel2. 1. From the Department of Neurology (M.d.B.), Haga Hospital, The Hague; the Department of Pediatric Neurology (M.E.), Emma Children's Hospital, Amsterdam; the Department of Neurology (M.E., B.M.v.G.), Academic Medical Center, University of Amsterdam; and the Department of Neurology (B.M.v.G.), Medical Center Alkmaar, the Netherlands. M.deBeer@hagaziekenhuis.nl. 2. From the Department of Neurology (M.d.B.), Haga Hospital, The Hague; the Department of Pediatric Neurology (M.E.), Emma Children's Hospital, Amsterdam; the Department of Neurology (M.E., B.M.v.G.), Academic Medical Center, University of Amsterdam; and the Department of Neurology (B.M.v.G.), Medical Center Alkmaar, the Netherlands.
Abstract
OBJECTIVE: To study the frequency of additional cerebral demyelination in Dutch patients with adrenomyeloneuropathy (AMN). METHODS: Consecutive patients with AMN from the Dutch X-linked adrenoleukodystrophy cohort without cerebral demyelination on MRI at inclusion, seen between January 1, 1992, and January 1, 1999, were included. Primary endpoints were brain involvement, death, or the end of follow-up on January 1, 2011. Three levels of certainty were used for cerebral demyelination: (1) signs and symptoms reported by relatives and treating physicians, confirmed by brain MRI; if follow-up MRIs were not available, (2) based upon information from treating physicians and relatives, and (3) based upon information obtained from relatives only. Results were compared with a study published in 2001, in which 13/68 (19.1%) patients with AMN developed cerebral demyelination in 9.5 ± 5.5 years. Differences of the proportions of patients with cerebral demyelination and their 95% confidence intervals (CIs) were calculated. RESULTS: Of 27 patients with AMN, 17 (63%) developed cerebral demyelination 10.2 ± 6.9 years after onset of myelo(neuro)pathy. Mean survival was 3.4 ± 2.9 years. Brain involvement was higher in Dutch patients with AMN (difference 44%, 95% CI 0.23-0.64). CONCLUSIONS: Cerebral demyelination in AMN may be more frequent than previously reported. Survival is as poor as in childhood cerebral adrenoleukodystrophy. Therapies that can halt cerebral demyelination in these patients are needed.
OBJECTIVE: To study the frequency of additional cerebral demyelination in Dutch patients with adrenomyeloneuropathy (AMN). METHODS: Consecutive patients with AMN from the Dutch X-linked adrenoleukodystrophy cohort without cerebral demyelination on MRI at inclusion, seen between January 1, 1992, and January 1, 1999, were included. Primary endpoints were brain involvement, death, or the end of follow-up on January 1, 2011. Three levels of certainty were used for cerebral demyelination: (1) signs and symptoms reported by relatives and treating physicians, confirmed by brain MRI; if follow-up MRIs were not available, (2) based upon information from treating physicians and relatives, and (3) based upon information obtained from relatives only. Results were compared with a study published in 2001, in which 13/68 (19.1%) patients with AMN developed cerebral demyelination in 9.5 ± 5.5 years. Differences of the proportions of patients with cerebral demyelination and their 95% confidence intervals (CIs) were calculated. RESULTS: Of 27 patients with AMN, 17 (63%) developed cerebral demyelination 10.2 ± 6.9 years after onset of myelo(neuro)pathy. Mean survival was 3.4 ± 2.9 years. Brain involvement was higher in Dutch patients with AMN (difference 44%, 95% CI 0.23-0.64). CONCLUSIONS:Cerebral demyelination in AMN may be more frequent than previously reported. Survival is as poor as in childhood cerebral adrenoleukodystrophy. Therapies that can halt cerebral demyelination in these patients are needed.
Authors: Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub Journal: Endocr Rev Date: 2020-08-01 Impact factor: 19.871
Authors: Craig V Baker; Alyssa Cady Keller; Richard Lutz; Karen Eveans; Krystal Baumert; James C DiPerna; William B Rizzo Journal: Int J Neonatal Screen Date: 2022-04-26
Authors: Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida Journal: J Inherit Metab Dis Date: 2018-02-01 Impact factor: 4.982
Authors: Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen Journal: Nat Rev Endocrinol Date: 2016-06-17 Impact factor: 43.330
Authors: Morten A Horn; Karin B M Mikaelsen; Sacha Ferdinandusse; Ellen Jørum; Svein I Mellgren; Lars Retterstøl; Ronald J A Wanders; Chantal M E Tallaksen Journal: Clin Case Rep Date: 2015-12-21
Authors: Aaron M Carlson; Irene C Huffnagel; Aad Verrips; Marjo S van der Knaap; Marc Engelen; Keith Van Haren Journal: J Neurol Date: 2020-09-29 Impact factor: 4.849
Authors: Malu-Clair van de Beek; Inge M E Dijkstra; Henk van Lenthe; Rob Ofman; Dalia Goldhaber-Pasillas; Nicolas Schauer; Martin Schackmann; Joo-Yeon Engelen-Lee; Frédéric M Vaz; Wim Kulik; Ronald J A Wanders; Marc Engelen; Stephan Kemp Journal: PLoS One Date: 2016-04-28 Impact factor: 3.240